Pomerantz LLP is investigating Beam Therapeutics and some of its executives for potential securities fraud following a press release on September 8, 2026. The release updated clinical trial data for BEAM-302, a treatment for alpha-1 antitrypsin deficiency, noting safety concerns including transient liver enzyme elevations. After this news, Beam's stock fell nearly 10%, signaling investor concern. The investigation could lead to legal action if wrongdoing is found.
Beam Therapeutics is the subject of an investor investigation following clinical trial safety concerns. For readers following the health sector, here is Pluang's market snapshot as of Sep 25, 2026 04:41 WIB: out of 100 priced US health stocks, 38 rose and 62 fell. Notable movers include NUWE at USD 0.80 with a 5.77% decline and a typical hold time of 23 days, DGX at USD 232.90 down 5.51% with a 55-day hold, and OSCR at USD 28.86 down 5.47% with a 14-day hold and near-even buy/sell order activity.
TD SYNNEX posted a record-breaking quarter in Q3 2026 with earnings and revenue surpassing expectations, driven by strong growth in its Hyve Solutions segment and AI infrastructure demand. Despite this, the stock dropped nearly 9% due to a nearly $1 ...
A crypto whale transferred 6,000 Ether (ETH), worth approximately $16.1 million, to five major cryptocurrency exchanges: OKX, Kraken, Gate, Bybit, and Binance. This large transfer places a significant amount of ETH on trading platforms, suggesting th...
Warren Buffett increased his stake in homebuilder Lennar to over 10% immediately after the company missed earnings and lowered its full-year delivery forecast. Despite Lennar's recent weak quarter, Buffett's move signals confidence in the long-term h...
TRON has exceeded $30 trillion in total transaction volume, marking its evolution into a high-throughput settlement network. Daily transactions exceed $30 billion, supported by over 405 million users and 15.6 billion processed transactions, mainly dr...
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
